SparingVision’s website
3 known investors
SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system. The company's lead candidate, SPVN06, is being evaluated in the PRODYGY clinical trial.
Investors · 3
Frequently asked questions
- What does SparingVision’s website do?
- SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system. The company's lead candidate, SPVN06, is being evaluated in the PRODYGY clinical trial.
- Who are SparingVision’s website's investors?
- SparingVision’s website's investors include AdBio partners, Jeito Capital, Ysios Capital.